Visible-Light-Induced Intramolecular C(sp<sup>2</sup>)–H Amination and Aziridination of Azidoformates via a Triplet Nitrene Pathway
作者:Yipin Zhang、Xunqing Dong、Yanan Wu、Guigen Li、Hongjian Lu
DOI:10.1021/acs.orglett.8b01980
日期:2018.8.17
Catalytic intramolecular C–H amination and aziridination reactions of o-allylphenyl azidoformates have been achieved under visible-light irradiation, providing a mild, clean, and efficient method for the synthesis of useful benzoxazolones and [5.1.0] bicyclic aziridines. Mechanistic studies suggest that a triplet nitrene acts as the reactive intermediate. The chemoselectivity of the reaction, with alkyl
The present invention provides compounds of formula I
1
and pharmaceutically acceptable salts thereof.
The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
[EN] NOVEL TYROSINE KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA TYROSINE KINASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2002079192A1
公开(公告)日:2002-10-10
The present invention provides compounds of formula I[ ] and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
The present invention provides compounds of formula I
and pharmaceutically acceptable salts thereof.
The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
Verfahren zur Verbesserung der Löslichkeit biologisch aktiver Wirkstoffe in Wasser und niederen aliphatischen Alkoholen sowie neue Verbindungen mit verbesserter Löslichkeit
申请人:BAYER AG
公开号:EP0014263A2
公开(公告)日:1980-08-20
Die Erfindung betrifft ein Verfahren zur Verbesserung der Löslichkeit biologisch aktiver Wirkstoffe, das dadurch gekennzeichnet ist, daß man biologisch aktive Wirkstoffe mit OH, NH oder NH2 monofunktionellen hydrophilen Polyathern und organischen Verbindungen mit mindestens 2 gegenüber Zerewitinoff-aktiven Wasserstoffatomen reaktiven Gruppen umsetzt. Sie betrifft ferner neue so hergestellte Verbindungen.